Company / R&D per Share
Taysha Gene Therapies, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.42
FY2025
5-year range
$0.30 / $3.50
FY2021-FY2025
Trend
+38.8%
vs FY2024
Sector context
#180 of 208
Health Care
What the data says
Taysha Gene Therapies, Inc.'s r&d per share of $0.42 is lower than 87% of companies in the Health Care sector (FY2025). R&D per Share returned to growth in FY2025 after 3 years of decline, reaching $0.42.
Based on SEC 10-K filings.
0.42 in FY2025 with a 5-year CAGR of -25.2%.
Declined from $1.44 to $0.42 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -50.3%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 208This company $0.42 Sector average $28.82
▼
-98.5% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 38.8% year-over-year.
- Ranks #180 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.42 | +38.8% |
| FY2024 | $0.30 | -78.9% |
| FY2023 | $1.44 | -57.9% |
| FY2022 | $3.43 | -2.1% |
| FY2021 | $3.50 | +94.1% |
| FY2020 | $1.81 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026